Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paramylon is a natural, linear β-1,3-D-glucan polysaccharide accumulated in crystalline form by the unicellular microalga *Euglena gracilis*, where it can constitute up to 30–70% of dry cell weight[1][3][4]. It acts as an *indigestible dietary fiber* and also exhibits immunomodulatory properties, including immunostimulation, anti-inflammatory, and anti-fibrotic effects. Paramylon is being investigated for health benefits such as suppression of chronic kidney disease progression (by reducing uremic toxin accumulation and renal inflammation), hepatoprotection, anti-allergy, antitumor activity, cholesterol lowering, antioxidant effects, and wound healing[1][2][3][4][5]. In animal models, it can attenuate kidney injury, moderate glucose and insulin responses, inhibit liver damage, suppress development of atopic dermatitis, and promote tissue healing. It is also used in aquaculture, as a feed additive to enhance immunity and mitigate stress. Mechanistically, paramylon's effects are attributed in part to its modulation of immune responses and gut microbiota, as well as inhibition of absorption of certain harmful metabolites and toxins[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paramylon.